Sector News

Charles River Labs cuts jobs as it closes San Diego site

April 3, 2019
Life sciences

After a number of pacts and buyouts over the past few years, Charles River Labs is cutting staff at one of its California sites.

According to a recent WARN notice, the CRO is cutting 24 employees from its San Diego site.

Charles River confirmed the cuts to FierceCRO today: “As part of our continuing efforts to streamline operations and enhance efficiencies, we have made the decision to close our research model production facility in San Diego and relocate all services and production to our Hollister site. Charles River is committed to maintaining its world-class client service and will ensure that the site closure will not impact availability or service.

“As part of this difficult but necessary decision, we are working with employees to ensure appropriate support and resources are in place as they seek new employment opportunities, both within and outside the company.”

Despite these cuts, over the past few months CRL has been spending, snapping up companies and making deals, including just two months back buying up early-stage CRO Citoxlab. A month before, it also went all-in for British CRO KWS BioTest in a £15 million ($20 million) deal. It’s also penned a new pact with Crown Bioscience for expanded access to the Zucker Diabetic Sprague-Dawley rat model.

By Ben Adams

Source: Fierce Biotech

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach